Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
1200 participants
OBSERVATIONAL
2020-07-01
2035-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main objectives are:
1. Monitor the incidence of COVID-19 and the development of the SARS-CoV-2-IgG levels of cases in Agder and Telemark over a period of two years (WP1).
2. Identify risk factors for COVID-19 by comparison of SARS-CoV-2 antibody positive and negative cases in Telemark and Agder, and comparison of these groups separately with population controls (WP2).
3. The incidence of neurocognitive symptoms and fatigue in COVID-19 patients (WP3).
4. Investigation of severity, death and the use of health care for the COVID-19 patients based on data from national registers (WP4).
The main exposures are (WP1-3):
* Infection (mild, severe) with COVID-19.
* Occupational risk factors assessed by occupational codes (ISCO88) and job exposure matrix categorisation.
* Environmental risk factors (road traffic outside bedroom window, travel by foot or bicycle alongside busy roads, and the use of a fireplaces in residential homes. Further, estimated measurements of air pollution may be linked to participants' home address.
* Socioeconomic status; age, sex, comorbidity, medication use, lifestyle factors (smoking, BMI, physical activity, others), geographic region/municipality, education and income.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SARS-CoV-2 PCR positive cases
Antibody tests will be performed every 6 months for 2 years
No interventions assigned to this group
SARS-CoV-2 PCR negative cases
Antibody tests will be performed at baseline
No interventions assigned to this group
Population controls
A large sample (n= 22500) from the general population will be included to assess risk factors. No blood sample will be collected for this group and the data needed is already collected.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Performed SARS-CoV-2 PCR test
Exclusion Criteria
* Deceased
* inability to answer questionnaire due to dementia or similar conditions
18 Years
85 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sorlandet Hospital HF
OTHER_GOV
Norwegian Institute of Public Health
OTHER_GOV
London School of Hygiene and Tropical Medicine
OTHER
Leiden University
OTHER
Aalborg University
OTHER
Sykehuset Telemark
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Anne Kristin M. Fell
Associate Professor, senior physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne Kristin M. Fell, PhD
Role: PRINCIPAL_INVESTIGATOR
Sykehuset Telemark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Telemark Hospital
Skien, Vestfold and Telemark, Norway
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sarjomaa M, Berg KK, Jaioun K, Tveten Y, Kersten H, Reiso H, Eikeland R, Thilesen C, Nordbo SA, Aaberge IS, Pearce N, Fell AKM. SARS-CoV-2-specific humoral immunity in a Norwegian cohort between 2020 and 2023. BMC Med. 2025 Jun 3;23(1):332. doi: 10.1186/s12916-025-04171-2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COVITA
Identifier Type: -
Identifier Source: org_study_id